Thyroid Cancer News

Targeted Therapies Show Initial Effectiveness in Subset of Papillary Thyroid Cancer (June 6, 2017)

Two immunotherapy drugs currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of melanoma also show promise for treating a rare but aggressive form of papillary thyroid cancer. Up to 44 percent of papillary thyroid cancer... Continue Reading

Thyroid Cancer Survivors May Have Increased Risk of Osteoporosis and Heart Conditions (March 3, 2017)

The results of a recent new study find that younger survivors of thyroid cancer are at increased risk for osteoporosis, high blood pressure and heart disease.  Thyroid cancer is the fifth most common cancer in women. The thyroid gland is a butterfly-shaped... Continue Reading

More Risk than Benefit with TSH Suppression in Thyroid Cancer without High Risk of Recurrence (May 21, 2015)

For patients undergoing treatment for thyroid cancer who aren’t at high risk of recurrence, therapy to suppress thyrotropin (TSH) may be ineffective as well as risky. These findings were published in the journal Thyroid. Differentiated thyroid cancer... Continue Reading

Target Therapy Sutent® Promising in Advanced Thyroid Cancer (May 19, 2015)

The targeted therapy Sutent® (sunitinib) appears effective in the treatment of patients with advanced differentiated thyroid cancers. The Endocrine Society announced these Phase II trial findings in a press release. Study results were also presented... Continue Reading

Important Clues in the Development of Aggressive Thyroid Cancer (April 16, 2015)

New insight into how anaplastic thyroid cancer (ATC) grows and spreads may provide important direction in the development of treatment. These findings were published in the Journal of Clinical Endocrinology and Metabolism. The thyroid is a gland in the... Continue Reading

Vandetanib Delays Progression of Advanced Medullary Thyroid Cancer (July 16, 2010)

Results of a Phase III clinical trial indicate that the investigational drug vandetanib delays the progression of locally advanced or metastatic medullary thyroid cancer. These results were presented at the 2010 annual meeting of the American Society... Continue Reading

Zactima Active Against Hereditary Medullary Thyroid Cancer (January 15, 2010)

Results of a Phase II clinical trial indicate that Zactima™ (vandetanib) has significant activity for the treatment of patients with advanced, hereditary medullary thyroid cancer. These results were published in the Journal of Clinical Oncology. Thyroid... Continue Reading

Latest Thyroid Cancer News By Stage


General Thyroid Cancer

Vandetanib Delays Progression of Advanced Medullary Thyroid Cancer (July 16, 2010)

Results of a Phase III clinical trial indicate that the investigational drug vandetanib delays the progression of locally advanced or metastatic medullary thyroid cancer. These results were presented at the 2010 annual meeting of the American Society... Continue Reading

More General Thyroid Cancer